title: rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.
abstract: Single nucleotide polymorphism (SNP) rs11671784 is in the loop of pre-miR-27a and the G/A variation can significantly decrease mature miR-27a expression. This study explored the role of miR-27a in chemo-sensitivity of bladder cancer and how rs11671784 G/A variation affects the sensitivity. Blood and tumor samples from 89 bladder cancer cases were analyzed. In-vitro study was performed to explore the mechanism of chemo-sensitivity and the downstream target of miR-27a by using bladder cancer cell lines. This study identified a causative relationship between rs11671784 G/A variation, lowered miR-27a expression, increased RUNX-1 expression and following weakened chemo-sensitivity. rs11671784 G allele has significantly stronger effect over A allele in promoting chemo-sensitivity in bladder cancer. miR-27a mediates chemotherapy at least partially through reducing P-gp expression and increasing apoptosis. In addition, RUNX-1 is a novel direct target of miR-27a, which is involved in its regulation of chemo-sensitivity in bladder cancer.
authors: Department of Oncology, Sichuan Provincial People's Hospital, School of Clinical Medicine of University of Electronic Science and Technology of China, Chengdu 610000, China.
authors: Ying
authors: Y
authors: Deng
authors: Department of Oncology, Sichuan Provincial People's Hospital, School of Clinical Medicine of University of Electronic Science and Technology of China, Chengdu 610000, China; Graduate School, Zunyi Medical College, Zunyi 563000, China.
authors: Hansong
authors: H
authors: Bai
authors: Department of Oncology, Sichuan Provincial People's Hospital, School of Clinical Medicine of University of Electronic Science and Technology of China, Chengdu 610000, China. Electronic address: 754417834@qq.com.
authors: Honglin
authors: H
authors: Hu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D018390:Gene Targeting / Q000379:methods*; D005819:Genetic Markers / Q000235:genetics; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D017239:Paclitaxel / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D005819:Genetic Markers; C531388:MIRN27 microRNA, human; D035683:MicroRNAs; C493728:RUNX1 protein, human; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin
keywords: Bladder cancer; Chemotherapy resistance; miR-27a; rs11671784